IQVIA Holdings Inc. (NYSE:IQV) Director John G. Danhakl Purchases 1,275 Shares

IQVIA Holdings Inc. (NYSE:IQV) Director John G. Danhakl acquired 1,275 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The shares were bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the acquisition, the director now owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

IQVIA Trading Down 0.9 %

IQV stock opened at $208.13 on Friday. The firm has a market cap of $37.78 billion, a P/E ratio of 27.75, a PEG ratio of 2.25 and a beta of 1.48. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company’s 50-day simple moving average is $200.53 and its 200-day simple moving average is $219.80.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 10.81 EPS for the current fiscal year.

Institutional Trading of IQVIA

A number of institutional investors and hedge funds have recently modified their holdings of IQV. Private Trust Co. NA increased its stake in IQVIA by 10.7% during the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after buying an additional 47 shares in the last quarter. Clear Harbor Asset Management LLC lifted its holdings in IQVIA by 1.3% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock valued at $941,000 after purchasing an additional 50 shares in the last quarter. Pine Valley Investments Ltd Liability Co boosted its stake in IQVIA by 0.5% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock worth $2,247,000 after purchasing an additional 50 shares during the last quarter. Howard Capital Management Inc. raised its position in shares of IQVIA by 4.9% in the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock valued at $225,000 after buying an additional 54 shares during the last quarter. Finally, Fortitude Family Office LLC lifted its stake in shares of IQVIA by 2.9% in the third quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company’s stock worth $468,000 after buying an additional 56 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on IQV shares. Robert W. Baird cut their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Barclays reduced their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research note on Wednesday, December 11th. TD Cowen reduced their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, Stifel Nicolaus dropped their target price on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research report on Friday. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $252.39.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.